UA126381C2 - Нові антитіла, які специфічно зв'язуються з епітопами вірусу зіка, та їх застосування - Google Patents
Нові антитіла, які специфічно зв'язуються з епітопами вірусу зіка, та їх застосування Download PDFInfo
- Publication number
- UA126381C2 UA126381C2 UAA201901101A UAA201901101A UA126381C2 UA 126381 C2 UA126381 C2 UA 126381C2 UA A201901101 A UAA201901101 A UA A201901101A UA A201901101 A UAA201901101 A UA A201901101A UA 126381 C2 UA126381 C2 UA 126381C2
- Authority
- UA
- Ukraine
- Prior art keywords
- same
- antibody
- antigen
- amino acid
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/066684 WO2018010789A1 (en) | 2016-07-13 | 2016-07-13 | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
| PCT/EP2017/067581 WO2018011283A1 (en) | 2016-07-13 | 2017-07-12 | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA126381C2 true UA126381C2 (uk) | 2022-09-28 |
Family
ID=56413654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201901101A UA126381C2 (uk) | 2016-07-13 | 2017-07-12 | Нові антитіла, які специфічно зв'язуються з епітопами вірусу зіка, та їх застосування |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US11117954B2 (https=) |
| EP (2) | EP3484915B1 (https=) |
| JP (2) | JP7252888B2 (https=) |
| KR (1) | KR102595764B1 (https=) |
| CN (2) | CN109563157B (https=) |
| AU (1) | AU2017297757B2 (https=) |
| BR (1) | BR112018074456A2 (https=) |
| CA (1) | CA3024374A1 (https=) |
| CL (2) | CL2019000067A1 (https=) |
| CO (1) | CO2019001111A2 (https=) |
| CR (1) | CR20190066A (https=) |
| DK (1) | DK3484915T5 (https=) |
| DO (2) | DOP2019000006A (https=) |
| EA (1) | EA201990243A1 (https=) |
| EC (1) | ECSP19009170A (https=) |
| ES (1) | ES2959883T3 (https=) |
| FI (1) | FI3484915T3 (https=) |
| HR (1) | HRP20231196T1 (https=) |
| HU (1) | HUE063272T2 (https=) |
| IL (1) | IL262710B2 (https=) |
| LT (1) | LT3484915T (https=) |
| MX (1) | MX2019000526A (https=) |
| MY (1) | MY190553A (https=) |
| PE (1) | PE20190398A1 (https=) |
| PH (1) | PH12018502348B1 (https=) |
| PL (1) | PL3484915T3 (https=) |
| SG (1) | SG11201809879WA (https=) |
| SI (1) | SI3484915T1 (https=) |
| UA (1) | UA126381C2 (https=) |
| WO (2) | WO2018010789A1 (https=) |
| ZA (1) | ZA201807467B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6998935B2 (ja) | 2016-07-13 | 2022-01-18 | エボニック オペレーションズ ゲーエムベーハー | 溶解された脂質含有バイオマスから脂質を分離する方法 |
| SG10201912925SA (en) | 2016-10-13 | 2020-02-27 | Massachusetts Inst Technology | Antibodies that bind zika virus envelope protein and uses thereof |
| WO2019042555A1 (en) | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF |
| EP3527664A1 (en) | 2018-02-15 | 2019-08-21 | Evonik Degussa GmbH | Method of isolating lipids from a lipids containing biomass |
| JP2019152666A (ja) * | 2018-03-02 | 2019-09-12 | 富士レビオ株式会社 | ジカウイルスを検出する方法及びキット |
| WO2019209974A2 (en) | 2018-04-24 | 2019-10-31 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination |
| WO2019219396A1 (en) | 2018-05-15 | 2019-11-21 | Evonik Operations Gmbh | Method of isolating lipids from a lysed lipids containing biomass by emulsion inversion |
| EP3794097B1 (en) | 2018-05-15 | 2024-10-23 | Evonik Operations GmbH | Method of isolating lipids from a lipids containing biomass with aid of hydrophobic silica |
| WO2020061159A1 (en) * | 2018-09-20 | 2020-03-26 | Vanderbilt University | Human antibodies to zika virus |
| WO2020078568A1 (en) | 2018-10-19 | 2020-04-23 | Humabs Biomed Sa | Antibodies and methods for treatment of lyssavirus infection |
| WO2020092564A1 (en) * | 2018-10-31 | 2020-05-07 | Icahn School Of Medicine At Mount Sinai | Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof |
| WO2020106358A1 (en) | 2018-11-20 | 2020-05-28 | Takeda Vaccines, Inc. | Novel anti-zika virus antibodies and uses thereof |
| WO2020245663A1 (en) * | 2019-06-01 | 2020-12-10 | Institut Pasteur | Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection |
| WO2021050989A1 (en) * | 2019-09-13 | 2021-03-18 | Duke University | Zika antibodies and their use |
| JP7725465B2 (ja) * | 2019-11-07 | 2025-08-19 | 中国科学院微生物研究所 | ジカ・デングワクチン及びその使用 |
| KR20220103761A (ko) * | 2019-11-19 | 2022-07-22 | 벤더르빌트 유니버시티 | 지카 바이러스를 중화하는 인간 항체 및 이의 사용 방법 |
| CN111138534B (zh) * | 2019-12-31 | 2021-09-28 | 武汉班科生物技术股份有限公司 | 寨卡病毒囊膜蛋白的鼠源单克隆抗体 |
| CN111100201B (zh) * | 2019-12-31 | 2021-09-28 | 武汉班科生物技术股份有限公司 | 针对寨卡病毒囊膜蛋白的鼠源单克隆抗体 |
| JP7471555B2 (ja) * | 2020-02-20 | 2024-04-22 | 国立感染症研究所長 | フラビウイルス交差中和抗体及び医薬組成物 |
| JP2023527169A (ja) | 2020-05-20 | 2023-06-27 | タケダ ワクチン，インコーポレイテッド | 抗原の効力を決定するための方法 |
| JP2023526493A (ja) | 2020-05-20 | 2023-06-21 | タケダ ワクチン，インコーポレイテッド | ジカウイルス特異的抗体の検出方法 |
| WO2021236225A1 (en) | 2020-05-20 | 2021-11-25 | Takeda Vaccines, Inc. | Method for detection of zika virus specific antibodies |
| CN115697392B (zh) * | 2020-06-28 | 2026-03-13 | 神州细胞工程有限公司 | 一种降低病毒ade效应的方法 |
| EP4313102A4 (en) * | 2021-04-01 | 2025-02-26 | A2 Biotherapeutics, Inc. | POLYPEPTIDES TARGETING HLA-A*11 AND METHODS OF USE THEREOF |
| CN112921124B (zh) * | 2021-04-08 | 2021-09-28 | 广东创晟控股集团有限公司 | 一种快速检测病毒的试剂盒 |
| WO2024211789A1 (en) * | 2023-04-07 | 2024-10-10 | Fred Hutchinson Cancer Center | Cross-flavivirus binding domains and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3766162A (en) | 1971-08-24 | 1973-10-16 | Hoffmann La Roche | Barbituric acid antigens and antibodies specific therefor |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| US20020102208A1 (en) | 1999-03-01 | 2002-08-01 | Paul Chinn | Radiolabeling kit and binding assay |
| MY133346A (en) | 1999-03-01 | 2007-11-30 | Biogen Inc | Kit for radiolabeling ligands with yttrium-90 |
| AU2003263853A1 (en) * | 2002-08-16 | 2004-03-03 | Board Of Regents The University Of Texas System | Compositions and methods related to flavivirus envelope protein domain iii antigens |
| WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| CA2529945A1 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| MX2009012343A (es) | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| BRPI0914092B1 (pt) | 2008-10-22 | 2021-08-31 | Institute For Research In Biomedicine | Método de produção de um anticorpo a partir de células plasmáticas, método de produção de um anticorpo monoclonal a partir de células plasmáticas e método de produção de um anticorpo ou de um fragmento de anticorpo |
| MX367668B (es) * | 2013-03-15 | 2019-08-30 | Dana Farber Cancer Inst Inc | Anticuerpos neutralizadores de flavivirus y métodos de uso de los mismos. |
| AU2017230112A1 (en) | 2016-03-11 | 2018-10-04 | The Johns Hopkins University | Live attenuated Zika virus vaccine |
| WO2017181098A2 (en) * | 2016-04-15 | 2017-10-19 | Visterra, Inc. | Antibody molecules to zika virus and uses thereof |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| KR102717819B1 (ko) | 2017-07-28 | 2024-10-14 | 다케다 야쿠힌 고교 가부시키가이샤 | Tyk2 억제제 및 이의 용도 |
-
2016
- 2016-07-13 WO PCT/EP2016/066684 patent/WO2018010789A1/en not_active Ceased
-
2017
- 2017-07-12 ES ES17742985T patent/ES2959883T3/es active Active
- 2017-07-12 UA UAA201901101A patent/UA126381C2/uk unknown
- 2017-07-12 US US16/317,533 patent/US11117954B2/en not_active Expired - Fee Related
- 2017-07-12 PL PL17742985.9T patent/PL3484915T3/pl unknown
- 2017-07-12 BR BR112018074456-5A patent/BR112018074456A2/pt not_active IP Right Cessation
- 2017-07-12 FI FIEP17742985.9T patent/FI3484915T3/fi active
- 2017-07-12 WO PCT/EP2017/067581 patent/WO2018011283A1/en not_active Ceased
- 2017-07-12 DK DK17742985.9T patent/DK3484915T5/da active
- 2017-07-12 PH PH1/2018/502348A patent/PH12018502348B1/en unknown
- 2017-07-12 HU HUE17742985A patent/HUE063272T2/hu unknown
- 2017-07-12 JP JP2019501482A patent/JP7252888B2/ja active Active
- 2017-07-12 CR CR20190066A patent/CR20190066A/es unknown
- 2017-07-12 PE PE2019000034A patent/PE20190398A1/es unknown
- 2017-07-12 EP EP17742985.9A patent/EP3484915B1/en active Active
- 2017-07-12 IL IL262710A patent/IL262710B2/en unknown
- 2017-07-12 EP EP23191207.2A patent/EP4342911A1/en not_active Withdrawn
- 2017-07-12 MY MYPI2018704108A patent/MY190553A/en unknown
- 2017-07-12 CN CN201780042888.7A patent/CN109563157B/zh active Active
- 2017-07-12 CA CA3024374A patent/CA3024374A1/en active Pending
- 2017-07-12 EA EA201990243A patent/EA201990243A1/ru unknown
- 2017-07-12 LT LTEPPCT/EP2017/067581T patent/LT3484915T/lt unknown
- 2017-07-12 SI SI201731420T patent/SI3484915T1/sl unknown
- 2017-07-12 AU AU2017297757A patent/AU2017297757B2/en not_active Expired - Fee Related
- 2017-07-12 SG SG11201809879WA patent/SG11201809879WA/en unknown
- 2017-07-12 HR HRP20231196TT patent/HRP20231196T1/hr unknown
- 2017-07-12 MX MX2019000526A patent/MX2019000526A/es unknown
- 2017-07-12 CN CN202211721078.3A patent/CN116199775A/zh active Pending
- 2017-07-12 KR KR1020197004192A patent/KR102595764B1/ko active Active
-
2018
- 2018-11-07 ZA ZA2018/07467A patent/ZA201807467B/en unknown
-
2019
- 2019-01-08 DO DO2019000006A patent/DOP2019000006A/es unknown
- 2019-01-09 CL CL2019000067A patent/CL2019000067A1/es unknown
- 2019-02-05 CO CONC2019/0001111A patent/CO2019001111A2/es unknown
- 2019-02-07 EC ECSENADI20199170A patent/ECSP19009170A/es unknown
-
2021
- 2021-02-10 DO DO2021000026A patent/DOP2021000026A/es unknown
- 2021-06-01 US US17/335,792 patent/US11912757B2/en active Active
- 2021-06-01 US US17/335,799 patent/US20210363227A1/en not_active Abandoned
- 2021-11-12 CL CL2021002994A patent/CL2021002994A1/es unknown
-
2023
- 2023-02-10 JP JP2023019144A patent/JP2023062036A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA126381C2 (uk) | Нові антитіла, які специфічно зв'язуються з епітопами вірусу зіка, та їх застосування | |
| CN102164613B (zh) | 中和抗甲型流感病毒抗体及其用途 | |
| CN102272155B (zh) | 登革热病毒中和抗体及其用途 | |
| CN105050621B (zh) | 防止和治疗多发性硬化症的方法 | |
| KR101514682B1 (ko) | 인간 ｂ 세포에서 생산된 인플루엔자 ａ 바이러스 중화 활성을 가지는 결합 분자 | |
| KR20200042499A (ko) | 지카 바이러스 에피토프에 특이적으로 결합하는 다중특이적 항체 및 이의 용도 | |
| TWI854285B (zh) | 抗體介導屈公(chikungunya)病毒中和 | |
| EA038301B1 (ru) | Антитела, которые эффективно нейтрализуют вирус гепатита в, и их применение | |
| EA030319B1 (ru) | Антитела, нейтрализующие rsv, mpv и pvm, и их применения | |
| WO2018022786A1 (en) | Antibodies to zika virus and methods of use thereof | |
| US12534517B2 (en) | Highly specific zika neutralizing human antibodies | |
| Acciani et al. | Uncovering the features of Measles-targeting human antibodies elicited by the MMR vaccine | |
| US20260078170A1 (en) | Pan-Neutralizing SARS-CoV-2 mAb Composition and Methods of Treatment Thereof | |
| Choudhary et al. | Broad-Spectrum Heavily Mutated Monoclonal Antibody Isolated from COVID-19 Convalescent Vaccinee with Capacity to Neutralize SARS-CoV2 Variants Ranging from B. 1 to BQ. 1.1. | |
| EA046175B1 (ru) | Выделенное антитело или его антигенсвязывающий фрагмент, которые специфически связываются с эпитопом вируса зика, их получение и применения | |
| EA043940B1 (ru) | Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение | |
| HK40002097A (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| HK40002097B (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| HK40006233B (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| BR122024006890A2 (pt) | Anticorpo isolado, ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, vetor, célula, composição farmacêutica, uso dos mesmos, kit de partes, bem como ensaio de bloqueio de ligação para diagóstico in vitro de infecção por zika vírus |